Reformulating a novel therapeutic for lung cancer

London-based ValiSeek is developing VAL401, a repurposed treatment for lung and other cancers that is now ready for partnering.

Like Comment
Page of
Go to the profile of ValiSeek


ValiSeek Limited was formed as a Joint Venture single asset company in 2014 to progress cancer program VAL401 through early stage clinical trials to a stage attractive for out-licensing. ValiSeek is looking to initiate detailed licensing discussions prior to completion for co-development or out-licensing on a regional, global or disease specific basis to ensure a smooth continuation of their project VAL401.

No comments yet.